US FDA Inspection at Pashmylaram Facility, Hyderabad of Gland Pharma Ltd

The United States Food and Drug Administration (US FDA) has conducted Pre-Approval Inspection (PAI) for Seven (7) Products and Good Manufacturing Practice (GMP) Inspection at the Company's Pashamylaram Facility at Hyderabad between 15th June 2023 and 27th June 2023.

The inspection was concluded with ONE (1) 483 Observation. This observation is procedural in nature and the corrective and preventive actions for this observation will be submitted to the US FDA within the stipulated period. The observation issued is neither a repeated observation nor related to data integrity.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1014.60 as compared to the previous close of Rs. 1019.45. The total number of shares traded during the day was 7722 in over 573 trades.

The stock hit an intraday high of Rs. 1028.75 and intraday low of 1011.00. The net turnover during the day was Rs. 7859206.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 USFDA PreApprovalInspection GMP PashamylaramFacility